Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis
Read Article
News
2024
2023
Archive
Search news articles
October 18, 2017
VIVEVE RELEASES PRELIMINARY THIRD QUARTER 2017 FINANCIAL RESULTS
October 16, 2017
APREA THERAPEUTICS ANNOUNCES FIRST PATIENTS ENROLLED IN PHASE IB/II CLINICAL STUDY OF APR-246 FOR THE TREATMENT OF ESOPHAGEAL CANCER
October 6, 2017
FLEXION THERAPEUTICS ANNOUNCES FDA APPROVAL OF ZILRETTA™ (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION) FOR OSTEOARTHRITIS (OA) KNEE PAIN
October 3, 2017
IMPEL NEUROPHARMA BOARD ANNOUNCES APPOINTMENT OF JON CONGLETON AS CEO
September 29, 2017
NOHLA THERAPEUTICS AWARDED $6.9 MILLION GRANT FROM CIRM FOR THE TREATMENT OF PATIENTS WITH ACUTE MYELOID LEUKEMIA
September 27, 2017
FDA SELECTS PARTICIPANTS FOR NEW DIGITAL HEALTH SOFTWARE PRE-CERTIFICATION PILOT PROGRAM; INCLUDES PEAR THERAPEUTICS
September 27, 2017
AUDENTES THERAPEUTICS ANNOUNCES RARE PEDIATRIC DISEASE AND FAST TRACK DESIGNATIONS FOR AT132 FOR THE TREATMENT OF X-LINKED MYOTUBULAR MYOPATHY
September 21, 2017
AUDENTES THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 FOR THE TREATMENT OF X-LINKED MYOTUBULAR MYOPATHY
September 20, 2017
ARVINAS APPOINTS DR. JOHN HOUSTON AS PRESIDENT AND CHIEF EXECUTIVE OFFICER
September 15, 2017
PEAR THERAPEUTICS OBTAINS FDA CLEARANCE OF THE FIRST PRESCRIPTION DIGITAL THERAPEUTIC TO TREAT DISEASE
« Previous Page
1
2
3
4
5
…
8
Next Page »